• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Neurodegenerative Diseases Market to 2018 - New Product Entries in both Niche and Broader Parkinson’s Disease Treatment will Boost Market Despite Patent Cliff - Product Image

Neurodegenerative Diseases Market to 2018 - New Product Entries in both Niche and Broader Parkinson’s Disease Treatment will Boost Market Despite Patent Cliff

  • Published: March 2013
  • Region: Global
  • 184 Pages
  • GBI Research

“Neurodegenerative Diseases Market to 2018 - New Product Entries in both Niche and Broader Parkinson’s Disease Treatment will Boost Market Despite Patent Cliff”. A highly dynamic market scenario is expected in Neurodegenerative diseases in the next few years, with a number of patent expiries and anticipated new drug approvals. The market for Alzheimer’s disease has not seen any recent major breakthroughs, and is expected to experience a decline due to the patent expiry of several major products.

The market for Parkinson’s disease, on the other hand, is expected to experience growth due to the anticipated approval of expensive products such as Duodopa in the US, in spite of the fact that it will soon hit its own patent cliff. Additionally, the overall aging of populations the developed world is expected to increase the number of patients suffering from these diseases due to their relatively high prevalence in the elderly.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis, and key M&A and licensing deal trends in Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic READ MORE >

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Neurodegenerative Diseases Market to 2018: Introduction

3 Neurodegenerative Diseases Market to 2018: Global Market Overview

3.1 Revenue
3.2 Treatment Usage Pattern
3.3 Distribution by Market
3.4 Drivers and Restraints of the Neurodegenerative Diseases Market
3.4.1 Drivers
3.4.2 Restraints

4 Therapeutic Landscape

4.1 Market for Alzheimer’s Disease
4.1.1 Introduction
4.1.2 Revenue and Forecasts
4.1.3 Treatment Usage Pattern
4.1.4 Geographical Landscape
4.1.5 Drivers and Restraints for the Alzheimer’s Disease Market
4.2 Market for Parkinson’s Disease
4.2.1 Introduction
4.2.2 Revenue and Forecasts
4.2.3 Treatment Usage Pattern
4.2.4 Geographical Landscape
4.2.5 Drivers and Restraints for the Parkinson’s Disease Market
4.3 Market for Amyotrophic Lateral Sclerosis
4.3.1 Introduction
4.3.2 Revenue and Forecasts
4.3.3 Treatment Usage Pattern
4.3.4 Geographical Landscape
4.3.5 Drivers and Restraints for the Amyotrophic Lateral Sclerosis Market
4.4 Market for Huntington’s Disease
4.4.1 Introduction
4.4.2 Revenue and Forecasts
4.4.3 Treatment Usage Pattern
4.4.4 Geographical Landscape
4.4.5 Drivers and Restraints for the Huntington’s Disease Market

5 Neurodegenerative Diseases Market: Pipeline Analysis

5.1 Introduction
5.2 Summary of the Current Neurodegenerative Diseases R&D Pipeline
5.2.1 Alzheimer's Disease
5.2.2 Amyotrophic Lateral Sclerosis
5.2.3 Parkinson’s Disease
5.2.4 Huntington’s Disease

6 Neurodegenerative Diseases Market: Deals and Strategic Consolidations

6.1 Merger and Acquisition Deals
6.1.1 Sanofi-Synthelabo Merges with Aventis
6.1.2 Bayer Acquires Schering
6.1.3 Takeda Pharma Completes Acquisition of Nycomed International for $13,681m
6.1.4 Teva Pharma Acquires Ivax
6.1.5 Abbott Labs Acquires Solvay Pharma
6.1.6 Teva Completes Acquisition of Cephalon for $6.8 billion
6.1.7 UCB Acquires 87.62% Stake in Schwarz Pharma
6.1.8 Biovail Acquires Valeant Pharma
6.1.9 Dainippon Sumitomo Pharma Completes Acquisition of Sepracor for $2.6 Billion
6.1.10 Merck Acquires Banyu Pharma
6.1.11 Amgen Completes Acquisition of Micromet for $1.2 Billion
6.1.12 Bayer Acquires Minority Stake in Bayer Schering Pharma
6.1.13 Daiichi Sankyo Completes Acquisition of Plexxikon
6.1.14 Lundbeck Acquires Ovation Pharma
6.1.15 Eli Lilly and Company Acquires Avid RadioPharma
6.1.16 Abbott Labs Completes Acquisition of Facet Biotech
6.1.17 Biogen Idec Acquires Fumapharm
6.1.18 Upsher-Smith Completes Acquisition of Remaining 84% Stake in Proximagen for up to $555m
6.1.19 Sun Pharma Acquires Controlling Stake in Taro Pharma
6.1.20 Pfizer Acquires Rinat Neuroscience
6.1.21 Cubist Pharma Completes Acquisition of Adolor for $415m
6.1.22 Biogen Idec Acquires Panima Pharma
6.1.23 Teva Pharma Acquires CoGenesys from New Enterprise, Orbimed and Red Abbey
6.1.24 Fujifilm Holdings Acquires 66% Stake in Toyama Chemical
6.1.25 MGI PHARMA Acquires Guilford Pharma
6.1.26 H. Lundbeck Acquires LifeHealth
6.1.27 Endo Pharma Completes Acquisition of Penwest Pharma
6.1.28 EPIX Pharma Acquires Predix Pharma
6.1.29 Biogen Idec Acquires Syntonix Pharmaceuticals
6.1.30 Biotie Therapies Acquires Synosia Therapeutics
6.2 Licensing Agreements
6.2.1 Cephalon Enters into a Licensing Agreement with Mesoblast for Regenerative Medicine
6.2.2 Idera Pharma Enters into a Licensing Agreement with Merck
6.2.3 Astellas Pharma Enters into Licensing Agreement with CoMentis for Beta-Secretase Inhibitors
6.2.4 Synosia Therapeutics Enters into Licensing Agreement with UCB for SYN-115 and SYN-118
6.2.5 GlaxoSmithKline Signs an Agreement with AFFiRiS
6.2.6 Biogen Enters into an Agreement with Acorda Therapeutics
6.2.7 BioMS Medical Enters into Licensing Agreement with Eli Lilly
6.2.8 AC Immune Enters into Licensing Agreement with Genentech for Anti-Tau Antibodies
6.2.9 Biovail Enters into Licensing Agreement with Acadia Pharmaceuticals
6.2.10 Biogen Idec Enters into Licensing Agreement with Knopp Neurosciences for KNS-760704
6.2.11 AstraZeneca Enters into Licensing Agreement with Targacept
6.2.12 AC Immune Enters into Licensing Agreement with Genentech
6.2.13 Proximagen Enters into Licensing Agreement with Upsher-Smith Labs
6.2.14 Merck Serono Enters into Licensing Agreement with Apitope Technology
6.2.15 Serono Enters into Licensing Agreement with Newron Pharma for Safinamide
6.2.16 Shire Exercises Option to License Adenosine A2A from Heptares Therapeutics
6.2.17 GlaxoSmithKline Enters into Licensing Agreement with Impax Pharma for IPX066
6.2.18 Santhera Pharmaceuticals Enters into Licensing Agreement with Ipsen for Fipamezole
6.2.19 Domain Therapeutics Enters into Licensing Agreement with Merck Serono
6.2.20 Addex Pharma Enters into Collaboration and Licensing Agreement with Merck & Co
6.2.21 Curis Enters into Licensing Agreement with Wyeth Pharma
6.2.22 Pfizer Enters into a License and Collaboration Agreement with Transtech Pharma
6.2.23 Antisense Therapeutics Enters into Licensing Agreement with Teva Pharma
6.2.24 Biogen Idec Enters into Licensing Agreement with Vernalis
6.3 Co-Development Deals
6.3.1 GlaxoSmithKline Signs an Agreement with Targacept
6.3.2 GlaxoSmithKline Enters into an Agreement with EPIX Pharma
6.3.3 Evotec Enters into Co-Development Agreement with Roche
6.3.4 Pfizer Enters into Co-Development Agreement with Medivation for Dimebon
6.3.5 Alectos Therapeutics Enters into Research Collaboration with Merck & Co
6.3.6 Targacept Expands its Collaboration Agreement with AstraZeneca
6.3.7 Boehringer Ingelheim Partners with Vitae Pharma
6.3.8 Elan Enters into Co-Development Agreement with Transition Therapeutics
6.3.9 Ceregene Enters into Agreement with Genzyme

7 Appendix

7.1 Market Definitions
7.2 Abbreviations
7.3 Sources
7.4 Research Methodology
7.4.1 Coverage
7.4.2 Secondary Research
7.4.3 Primary Research
7.5 Therapeutic Landscape
7.5.1 Epidemiology-based Forecasting
7.5.2 Market Size by Geography
7.6 Geographical Landscape
7.7 Pipeline Analysis
7.8 Competitive Landscape
7.8.1 Expert Panel Validation
7.9 Contact Us
7.10 Disclaimer

1.1 List of Tables

Table 1: Neurodegenerative Diseases Market, Global, Revenue Forecast ($m), 2012–2018
Table 2: Neurodegenerative Diseases Market, Global, Revenue Forecast by Geography ($m), 2012–2018
Table 3: Neurodegenerative Diseases Market, Global, Treatment Usage Pattern (’000), 2012–2018
Table 4: Neurodegenerative Diseases Market, Global, Revenue Forecast by Market ($m), 2012–2018
Table 5: Alzheimer’s Disease Market, Global, Revenue Forecast ($m), 2012–2018
Table 6: Alzheimer’s Disease Market, Global, Treatment Usage Pattern (‘000), 2012–2018
Table 7: Alzheimer’s Disease Market, Global, Revenue Forecast by Geography ($m), 2012–2018
Table 8: Alzheimer’s Disease Market, Global, Revenue Forecast ($m), 2012–2018
Table 9: Alzheimer’s Disease Market, US, Annual Cost of Therapy ($), 2012–2018
Table 10: Alzheimer’s Disease Market, US, Treatment Usage Pattern (‘000), 2012–2018
Table 11: Alzheimer’s Disease Market, UK, Revenue Forecast ($m), 2012–2018
Table 12: Alzheimer’s Disease Market, UK, Annual Cost of Therapy ($), 2012–2018
Table 13: Alzheimer’s Disease Market, UK, Treatment Usage Pattern (‘000), 2012–2018
Table 14: Alzheimer’s Disease Market, Global, Revenue Forecast ($m), 2012–2018
Table 15: Alzheimer’s Disease Market, France, Annual Cost of Therapy ($), 2012–2018
Table 16: Alzheimer’s Disease Market, France, Treatment Usage Pattern (‘000), 2012–2018
Table 17: Alzheimer’s Disease Market, Germany, Revenue Forecast ($m), 2012–2018
Table 18: Alzheimer’s Disease Market, Germany, Annual Cost of Therapy ($), 2012–2018
Table 19: Alzheimer’s Disease Market, Germany, Treatment Usage Pattern (‘000), 2012–2018
Table 20: Alzheimer’s Disease Market, Italy, Revenue Forecast ($m), 2012–2018
Table 21: Alzheimer’s Disease Market, Italy, Annual Cost of Therapy ($), 2012–2018
Table 22: Alzheimer’s Disease Market, Italy, Treatment Usage Pattern (‘000), 2012–2018
Table 23: Alzheimer’s Disease Market, Spain, Revenue Forecast ($m), 2012–2018
Table 24: Alzheimer’s Disease Market, Spain, Annual Cost of Therapy ($), 2012–2018
Table 25: Alzheimer’s Disease Market, Spain, Treatment Usage Pattern (‘000), 2012–2018
Table 26: Alzheimer’s Disease Market, Japan, Revenue Forecast ($m), 2012–2018
Table 27: Alzheimer’s Disease Market, Japan, Annual Cost of Therapy ($), 2012–2018
Table 28: Alzheimer’s Disease Market, Japan, Treatment Usage Pattern (‘000), 2012–2018
Table 29: Parkinson’s Disease Market, Global, Revenue Forecast ($m), 2012–2018
Table 30: Parkinson’s Disease Market, Global, Treatment Usage Pattern (‘000), 2012–2018
Table 31: Parkinson’s Disease Market, Global, Revenue Forecast by Geography ($m), 2012–2018
Table 32: Parkinson’s Disease Market, US, Revenue Forecast ($m), 2012–2018
Table 33: Parkinson’s Disease Market, US, Annual Cost of Therapy ($), 2012–2018
Table 34: Parkinson’s Disease Market, US, Treatment Usage Pattern (‘000), 2012–2018
Table 35: Parkinson’s Disease Market, UK, Revenue Forecast ($m), 2012–2018
Table 36: Parkinson’s Disease Market, UK, Annual Cost of Therapy ($), 2012–2018
Table 37: Parkinson’s Disease Market, UK, Treatment Usage Pattern (‘000), 2012–2018
Table 38: Parkinson’s Disease Market, France, Revenue Forecast ($m), 2012–2018
Table 39: Parkinson’s Disease Market, France, Annual Cost of Therapy ($), 2012–2018
Table 40: Parkinson’s Disease Market, France, Treatment Usage Pattern (‘000), 2012–2018
Table 41: Parkinson’s Disease Market, Germany, Revenue Forecast ($m), 2012–2018
Table 42: Parkinson’s Disease Market, Germany, Annual Cost of Therapy ($), 2012–2018
Table 43: Parkinson’s Disease Market, Germany, Treatment Usage Pattern (‘000), 2012–2018
Table 44: Parkinson’s Disease Market, Italy, Revenue Forecast ($m), 2012–2018
Table 45: Parkinson’s Disease Market, Italy, Annual Cost of Therapy ($), 2012–2018
Table 46: Parkinson’s Disease Market, Italy, Treatment Usage Pattern (‘000), 2012–2018
Table 47: Parkinson’s Disease Market, Spain, Revenue Forecast ($m), 2012–2018
Table 48: Parkinson’s Disease Market, Spain, Annual Cost of Therapy ($), 2012–2018
Table 49: Parkinson’s Disease Market, Spain, Treatment Usage Pattern Forecast (‘000), 2012–2018
Table 50: Parkinson’s Disease Market, Japan, Revenue Forecast ($m), 2012–2018
Table 51: Parkinson’s Disease Market, Japan, Annual Cost of Therapy ($), 2012–2018
Table 52: Parkinson’s Disease Market, Japan, Treatment Usage Pattern (‘000), 2012–2018
Table 53: Amyotrophic Lateral Sclerosis Market, Global, Revenue Forecast ($m), 2012–2018
Table 54: Amyotrophic Lateral Sclerosis Market, Global, Treatment Usage Pattern (‘000), 2010–2018
Table 55: Amyotrophic Lateral Sclerosis Market, Global, Revenue Forecast by Geography ($m), 2012–2018
Table 56: Amyotrophic Lateral Sclerosis Market, US, Revenue Forecast ($m), 2012–2018
Table 57: Amyotrophic Lateral Sclerosis Market, US, Annual Cost of Therapy ($), 2012–2018
Table 58: Amyotrophic Lateral Sclerosis Market, US, Treatment Usage Pattern (‘000), 2012–2018
Table 59: Amyotrophic Lateral Sclerosis Market, UK, Revenue Forecast ($m), 2012–2018
Table 60: Amyotrophic Lateral Sclerosis Market, UK, Annual Cost of Therapy ($), 2012–2018
Table 61: Amyotrophic Lateral Sclerosis Market, UK, Treatment Usage Pattern (‘000), 2012–2018
Table 62: Amyotrophic Lateral Sclerosis Market, France, Revenue Forecast ($m), 2012–2018
Table 63: Amyotrophic Lateral Sclerosis Market, France, Annual Cost of Therapy ($), 2012–2018
Table 64: Amyotrophic Lateral Sclerosis Market, France, Treatment Usage Pattern (‘000), 2012–2018
Table 65: Amyotrophic Lateral Sclerosis Market, Germany, Revenue Forecast ($m), 2012–2018
Table 66: Amyotrophic Lateral Sclerosis Market, Germany, Annual Cost of Therapy ($), 2012–2018
Table 67: Amyotrophic Lateral Sclerosis Market, Germany, Treatment Usage Pattern (‘000), 2012–2018
Table 68: Amyotrophic Lateral Sclerosis Market, Italy, Revenue Forecast ($m), 2012–2018
Table 69: Amyotrophic Lateral Sclerosis Market, Italy, Annual Cost of Therapy ($), 2012–2018
Table 70: Amyotrophic Lateral Sclerosis Market, Italy, Treatment Usage Pattern (‘000), 2012–2018
Table 71: Amyotrophic Lateral Sclerosis Market, Spain, Revenue Forecast ($m), 2012–2018
Table 72: Amyotrophic Lateral Sclerosis Market, Spain, Annual Cost of Therapy ($), 2012–2018
Table 73: Amyotrophic Lateral Sclerosis Market, Spain, Treatment Usage Pattern (‘000), 2012–2018
Table 74: Amyotrophic Lateral Sclerosis Market, Japan, Revenue Forecast ($m), 2012–2018
Table 75: Amyotrophic Lateral Sclerosis Market, Japan, Annual Cost of Therapy ($), 2012–2018
Table 76: Amyotrophic Lateral Sclerosis Market, Japan, Treatment Usage Pattern (‘000), 2012–2018
Table 77: Huntington’s Disease Market, Global, Revenue Forecast ($m), 2012–2018
Table 78: Huntington’s Disease Market, Global, Treatment Usage Pattern (‘000), 2012–2018
Table 79: Huntington’s Disease Market, Global, Revenue Forecast by Geography ($m), 2012–2018
Table 80: Huntington’s Disease Market, US, Revenue Forecast ($m), 2012–2018
Table 81: Huntington’s Disease Market, US, Annual Cost of Therapy ($), 2012–2018
Table 82: Huntington’s Disease Market, US, Treatment Usage Pattern (‘000), 2012–2018
Table 83: Huntington’s Disease Market, UK, Revenue Forecast ($m), 2012–2018
Table 84: Huntington’s Disease Market, UK, Annual Cost of Therapy ($), 2012–2018
Table 85: Huntington’s Disease Market, UK, Treatment Usage Pattern (‘000), 2012–2018
Table 86: Huntington’s Disease Market, France, Revenue Forecast ($m), 2012–2018
Table 87: Huntington’s Disease Market, France, Annual Cost of Therapy ($), 2012–2018
Table 88: Huntington’s Disease Market, France, Treatment Usage Pattern (‘000), 2012–2018
Table 89: Huntington’s Disease Market, Germany, Revenue Forecast ($m), 2012–2018
Table 90: Huntington’s Disease Market, Germany, Annual Cost of Therapy ($), 2012–2018
Table 91: Huntington’s Disease Market, Germany, Treatment Usage Pattern (‘000), 2012–2018
Table 92: Huntington’s Disease Market, Italy, Revenue Forecast ($m), 2012–2018
Table 93: Huntington’s Disease Market, Italy, Annual Cost of Therapy ($), 2012–2018
Table 94: Huntington’s Disease Market, Italy, Treatment Usage Pattern (‘000), 2012–2018
Table 95: Huntington’s Disease Market, Spain, Revenue Forecast ($m), 2012–2018
Table 96: Huntington’s Disease Market, Spain, Annual Cost of Therapy ($), 2012–2018
Table 97: Huntington’s Disease Market, Spain, Treatment Usage Pattern (‘000), 2012–2018
Table 98: Huntington’s Disease Market, Japan, Revenue Forecast ($m), 2012–2018
Table 99: Huntington’s Disease Market, Japan, Annual Cost of Therapy ($), 2012–2018
Table 100: Huntington’s Disease Market, Japan, Treatment Usage Pattern (‘000), 2012–2018
Table 101: Neurodegenerative Diseases Market, Global, Alzheimer’s Disease Product Pipeline, 2012
Table 102: Neurodegenerative Diseases Market, Global, Amyotrophic Lateral Sclerosis Product Pipeline, 2012
Table 103: Neurodegenerative Diseases Market, Global, Parkinson’s Disease Product Pipeline, 2012
Table 104: Neurodegenerative Diseases Market, Global, Huntington’s Disease Product Pipeline, 2012

1.2 List of Figures

Figure 1: Neurodegenerative Diseases Market, Global, Revenue Forecast ($m), 2012–2018
Figure 2: Neurodegenerative Diseases Market, Global, Revenue Forecast by Geography ($m), 2012 and 2018
Figure 3: Neurodegenerative Diseases Market, Global, Treatment Usage Pattern (’000), 2012–2018
Figure 4: Neurodegenerative Diseases Market, Global, Revenue Forecast by Market (%), 2012 and 2018
Figure 5: Alzheimer’s Disease Market, Global, Revenue Forecast ($m), 2012–2018
Figure 6: Alzheimer’s Disease Market, Global, Treatment Usage Pattern (’000), 2012–2018
Figure 7: Alzheimer’s Disease Market, Global, Revenue Forecast by Geography ($m), 2012 and 2018
Figure 8: Alzheimer’s Disease Market, US, Revenue Forecast ($m), 2012–2018
Figure 9: Alzheimer’s Disease Market, US, Annual Cost of Therapy ($), 2012–2018
Figure 10: Alzheimer’s Disease Market, US, Treatment Usage Pattern (‘000), 2012–2018
Figure 11: Alzheimer’s Disease Market, UK, Revenue Forecast ($m), 2012–2018
Figure 12: Alzheimer’s Disease Market, UK, Annual Cost of Therapy ($), 2012–2018
Figure 13: Alzheimer’s Disease Market, UK, Treatment Usage Pattern (‘000), 2012–2018
Figure 14: Alzheimer’s Disease Market, France, Revenue Forecast ($m), 2012–2018
Figure 15: Alzheimer’s Disease Market, France, Annual Cost of Therapy ($), 2012–2018
Figure 16: Alzheimer’s Disease Market, France, Treatment Usage Pattern (‘000), 2012–2018
Figure 17: Alzheimer’s Disease Market, Germany, Revenue Forecast ($m), 2004–2018
Figure 18: Alzheimer’s Disease Market, Germany, Annual Cost of Therapy ($), 2012–2018
Figure 19: Alzheimer’s Disease Market, Germany, Treatment Usage Pattern (‘000), 2012–2018
Figure 20: Alzheimer’s Disease Market, Italy, Revenue Forecast ($m), 2012–2018
Figure 21: Alzheimer’s Disease Market, Italy, Annual Cost of Therapy ($), 2012–2018
Figure 22: Alzheimer’s Disease Market, Italy, Treatment Usage Pattern (‘000), 2012–2018
Figure 23: Alzheimer’s Disease Market, Spain, Revenue Forecast ($m), 2012–2018
Figure 24: Alzheimer’s Disease Market, Spain, Annual Cost of Therapy ($), 2012–2018
Figure 25: Alzheimer’s Disease Market, Spain, Treatment Usage Pattern (‘000), 2012–2018
Figure 26: Alzheimer’s Disease Market, Japan, Revenue Forecast ($m), 2012–2018
Figure 27: Alzheimer’s Disease Market, Japan, Annual Cost of Therapy ($), 2012–2018
Figure 28: Alzheimer’s Disease Market, Japan, Treatment Usage Pattern (‘000), 2012–2018
Figure 29: Parkinson’s Disease Market, Global, Revenue Forecast ($m), 2012–2018
Figure 30: Parkinson’s Disease Market Global, Treatment Usage Pattern (‘000), 2012–2018
Figure 31: Parkinson’s Disease Market, Global, Revenue Forecast by Geography ($m), 2012–2018
Figure 32: Parkinson’s Disease Market, US, Revenue Forecast ($m), 2012–2018
Figure 33: Parkinson’s Disease Market, US, Annual Cost of Therapy ($), 2012–2018
Figure 34: Parkinson’s Disease Market, US, Treatment Usage Pattern (‘000), 2012–2018
Figure 35: Parkinson’s Disease Market, UK, Revenue Forecast ($m), 2012–2018
Figure 36: Parkinson’s Disease Market, UK, Annual Cost of Therapy ($), 2012–2018
Figure 37: Parkinson’s Disease Market, UK, Treatment Usage Pattern (‘000), 2012–2018
Figure 38: Parkinson’s Disease Market, France, Revenue Forecast ($m), 2012–2018
Figure 39: Parkinson’s Disease Market, France, Annual Cost of Therapy ($), 2012–2018
Figure 40: Parkinson’s Disease Market, France, Treatment Usage Pattern (‘000), 2012–2018
Figure 41: Parkinson’s Disease Market, Germany, Revenue Forecast ($m), 2012–2018
Figure 42: Parkinson’s Disease Market, Germany, Annual Cost of Therapy ($), 2012–2018
Figure 43: Parkinson’s Disease Market, Germany, Treatment Usage Pattern (‘000), 2012–2018
Figure 44: Parkinson’s Disease Market, Italy, Revenue Forecast ($m), 2012–2018
Figure 45: Parkinson’s Disease Market, Italy, Annual Cost of Therapy ($), 2012–2018
Figure 46: Parkinson’s Disease Market, Italy, Treatment Usage Pattern (‘000), 2012–2018
Figure 47: Parkinson’s Disease Market, Spain, Revenue Forecast ($m), 2012–2018
Figure 48: Parkinson’s Disease Market, Spain, Annual Cost of Therapy ($), 2012–2018
Figure 49: Parkinson’s Disease Market, Spain, Treatment Usage Pattern (‘000), 2012–2018
Figure 50: Parkinson’s Disease Market, Japan, Revenue Forecast ($m), 2012–2018
Figure 51: Parkinson’s Disease Market, Japan, Annual Cost of Therapy ($), 2012–2018
Figure 52: Parkinson’s Disease Market, Japan, Treatment Usage Pattern (‘000), 2012–2018
Figure 53: Amyotrophic Lateral Sclerosis Market, Global, Revenue Forecast ($m), 2012–2018
Figure 54: Amyotrophic Lateral Sclerosis Market, Global, Treatment Usage Pattern (‘000), 2012–2018
Figure 55: Amyotrophic Lateral Sclerosis Market, Global, Revenue Forecast by Geography ($m), 2012–2018
Figure 56: Amyotrophic Lateral Sclerosis Market, US, Revenue Forecast ($m), 2012–2018
Figure 57: Amyotrophic Lateral Sclerosis Market, US, Annual Cost of Therapy ($), 2012–2018
Figure 58: Amyotrophic Lateral Sclerosis Market, US, Treatment Usage Pattern (‘000), 2012–2018
Figure 59: Amyotrophic Lateral Sclerosis Market, UK, Revenue Forecast ($m), 2012–2018
Figure 60: Amyotrophic Lateral Sclerosis Market, UK, Annual Cost of Therapy ($), 2012–2018
Figure 61: Amyotrophic Lateral Sclerosis Market, UK, Treatment Usage Pattern (‘000), 2012–2018
Figure 62: Amyotrophic Lateral Sclerosis Market, France, Revenue Forecast ($m), 2012–2018
Figure 63: Amyotrophic Lateral Sclerosis Market, France, Annual Cost of Therapy ($), 2012–2018
Figure 64: Amyotrophic Lateral Sclerosis Market, France, Treatment Usage Pattern (‘000), 2012–2018
Figure 65: Amyotrophic Lateral Sclerosis Market, Germany, Revenue Forecast ($m), 2012–2018
Figure 66: Amyotrophic Lateral Sclerosis Market, Germany, Annual Cost of Therapy ($), 2012–2018
Figure 67: Amyotrophic Lateral Sclerosis Market, Germany, Treatment Usage Pattern (‘000), 2012–2018
Figure 68: Amyotrophic Lateral Sclerosis Market, Italy, Revenue Forecast ($m), 2012–2018
Figure 69: Amyotrophic Lateral Sclerosis Market, Italy, Annual Cost of Therapy ($), 2012–2018
Figure 70: Amyotrophic Lateral Sclerosis Market, Italy, Treatment Usage Pattern (‘000), 2012–2018
Figure 71: Amyotrophic Lateral Sclerosis Market, Spain, Revenue Forecast ($m), 2012–2018
Figure 72: Amyotrophic Lateral Sclerosis Market, Spain, Annual Cost of Therapy ($), 2012–2018
Figure 73: Amyotrophic Lateral Sclerosis Market, Spain, Treatment Usage Pattern (‘000), 2012–2018
Figure 74: Amyotrophic Lateral Sclerosis Market, Japan, Revenue Forecast ($m), 2012–2018
Figure 75: Amyotrophic Lateral Sclerosis Market, Japan, Annual Cost of Therapy ($), 2012–2018
Figure 76: Amyotrophic Lateral Sclerosis Market, Japan, Treatment Usage Pattern (‘000), 2012–2018
Figure 77: Huntington’s Disease Market, Global, Revenue Forecast ($m), 2012–2018
Figure 78: Huntington’s Disease Market, Global, Treatment Usage Pattern (‘000), 2012–2018
Figure 79: Huntington’s Disease Market, Global, Revenue Forecast by Geography ($m), 2012–2018
Figure 80: Huntington’s Disease Market, US, Revenue Forecast ($m), 2012–2018
Figure 81: Huntington’s Disease Market, US, Annual Cost of Therapy ($), 2012–2018
Figure 82: Huntington’s Disease Market, US, Treatment Usage Pattern (‘000), 2012–2018
Figure 83: Huntington’s Disease Market, UK, Revenue Forecast ($m), 2012–2018
Figure 84: Huntington’s Disease Market, UK, Annual Cost of Therapy ($), 2012–2018
Figure 85: Huntington’s Disease Market, UK, Treatment Usage Pattern (‘000), 2012–2018
Figure 86: Huntington’s Disease Market, France, Revenue Forecast ($m), 2012–2018
Figure 87: Huntington’s Disease Market, France, Annual Cost of Therapy ($), 2012–2018
Figure 88: Huntington’s Disease Market, France, Treatment Usage Pattern (‘000), 2012–2018
Figure 89: Huntington’s Disease Market, Germany, Revenue Forecast ($m), 2012–2018
Figure 90: Huntington’s Disease Market, Germany, Annual Cost of Therapy ($), 2012–2018
Figure 91: Huntington’s Disease Market, Germany, Treatment Usage Pattern (‘000), 2012–2018
Figure 92: Huntington’s Disease Market, Italy, Revenue Forecast ($m), 2012–2018
Figure 93: Huntington’s Disease Market, Italy, Annual Cost of Therapy ($), 2012–2018
Figure 94: Huntington’s Disease Market, Italy, Treatment Usage Pattern (‘000), 2012–2018
Figure 95: Huntington’s Disease Market, Spain, Revenue Forecast ($m), 2012–2018
Figure 96: Huntington’s Disease Market, Spain, Annual Cost of Therapy ($), 2012–2018
Figure 97: Huntington’s Disease Market, Spain, Treatment Usage Pattern (‘000), 2012–2018
Figure 98: Huntington’s Disease Market, Japan, Revenue Forecast ($m), 2012–2018
Figure 99: Huntington’s Disease Market, Japan, Annual Cost of Therapy ($), 2012–2018
Figure 100: Huntington’s Disease Market, Japan, Treatment Usage Pattern (‘000), 2012–2018
Figure 101: Neurodegenerative Diseases Market, Global, Product Pipeline by Indication (%), 2012
Figure 102: Neurodegenerative Diseases Market, Global, Product Pipeline by Phase (%), 2012
Figure 103: Neurodegenerative Diseases Market, Global, Mergers and Acquisition Deals, 2004–2012
Figure 104: Neurodegenerative Diseases Market, Global, Mergers and Acquisition Deals, 2004–2012
Figure 105: Neurodegenerative Diseases Market, Licensing Agreements, 2004–2012
Figure 106: Neurodegenerative Diseases Market, Licensing Agreements (%), 2004–2012
Figure 107: Neurodegenerative Diseases Market, Co-Development Agreements, 2004–2012
Figure 108: Neurodegenerative Diseases Market, Co-Development Agreements (%), 2004–2012
Figure 109: Research Market Forecasting Model

Global Neurodegenerative Diseases Market to Witness Moderate Growth

The global neurodegenerative diseases market is expected to grow moderately from $8.8 billion in 2012 to $11 billion in 2018 at a Compound Annual Growth Rate (CAGR) of 1.8% from 2012–2015 and at a higher CAGR of 5.9% from 2015–2018. A number of competitive market entries are expected across all four indications during the forecast period, mitigating the effects of numerous patent expiries. In addition, growth in the population over the age of 65 across the seven major markets is expected to further drive this growth. The impact of these market entries is expected to present itself after 2015.

Alzheimer’s Disease and Parkinson’s Disease Therapeutics Account for the Majority of the Global Neurodegenerative Diseases Market

Due to their comparatively low prevalence rates, Huntington’s Disease (HS) and Amyotrophic Lateral Sclerosis (ALS) have relatively small disease markets. Parkinson’s Disease (PD) and Alzheimer’s Disease (AD) are the two dominant indications in the overall neurodegenerative diseases market. Due to the anticipated approval of a number of competitive treatments during the forecast period, the PD market is expected to contribute far more to the overall neurodegenerative diseases market by 2018.

Strong Product Pipeline to Ensure the Future Growth of the Neurodegenerative Diseases Market

In spite of a number of high-profile clinical trial failures such as bapineuzumab and, to an extent, solanezumab for the treatment of AD, the overall pipeline for neurodegenerative diseases remains strong. It contains an estimated 678 pipeline products, most of which are being developed for the treatment of AD or PD. There are relatively few products in Phase III development, although Phases I and II are relatively populated with a variety of molecules. The largest stage of development in terms of the number of molecules is the Preclinical stage, which accounts for 42% of the pipeline with 288 molecules identified at this stage.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos